Sophia Genetics is a biotechnology company that specializes in the application of artificial intelligence and data analytics to genomic medicine. By harnessing advanced algorithms and a robust cloud-based platform, the company empowers hospitals and healthcare institutions to interpret and analyze genomic data more effectively. Their focus is on enhancing precision medicine by enabling better diagnosis and treatment options for patients with various genetic diseases and cancers. Through collaboration with healthcare providers, Sophia Genetics aims to improve patient outcomes by integrating genomic insights into clinical workflows, ultimately driving innovation in the field of personalized medicine. Read More
San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic move marks a significant pivot for the genomic sequencing giant, as it ventures deeper into the burgeoning fields
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.
